Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for exercise tolerance in heart failure with preserved ejection fraction
ChiCTR2300072908Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in heart failure with preserved ejection fraction (HFpEF) comparing Empagliflozin intervention group with Observation group (2 arms). Primary endpoints: Peak oxygen uptake, Peak oxygen pulse and 2 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2300072908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072908.